10 stories found
Rigel Pharmaceuticals and Protagonist Therapeutics have announced plans to participate in upcoming investor and investment bank conferences scheduled for September. The events will provide platforms for management teams to present corporate updates and financial outlooks to market participants.
The US Food and Drug Administration has granted approval to Takeda Pharmaceutical’s drug Mimrylo for the treatment of polycythemia vera. The medication targets patients with this rare myeloproliferative neoplasm, offering a new therapeutic option.
Billionaire investor Tom Steyer has reportedly increased his holdings in several companies, including tech giants like Microsoft and Amazon, and various pharmaceutical firms. His recent investment activities indicate a bullish outlook on these specific stocks.
A director at Protagonist Therapeutics has sold 20,000 shares of the company's stock, occurring during a period of strong performance for the company's shares.
Investment analysts have increased their valuation forecast for Protagonist Therapeutics following regulatory approval for its Mimrylo treatment.
Protagonist Therapeutics received an upgrade from Goldman Sachs, citing the potential of its autoimmune asset. This financial news highlights investor confidence in the company's pharmaceutical developments.
Billionaire investor Howard Marks has shown bullish positions in several companies, including Core Scientific, Expand Energy, Telephone and Data Systems, and Bausch Health, while trimming his stake in Garrett Motion. Separately, billionaire Joe Edelman expressed a positive outlook on Protagonist Therapeutics.
Investment firms Clear Street and Jefferies reiterated buy ratings for Protagonist Therapeutics, pointing to the commercial strength of its Mimrylo label. Meanwhile, Morningstar affirmed its support for Bunzl, noting that current share prices remain undervalued relative to the company's competitive advantages.
An analysis questions why Wall Street is reportedly optimistic about Protagonist Therapeutics stock, suggesting a potential misjudgment of its value.
An analysis explores whether Protagonist Therapeutics' (PTGX) derisked drugs have the potential to become blockbuster medications, impacting the company's future market performance.